Skip to main content
Premium Trial:

Request an Annual Quote

Alithea Genomics Raises CHF 1M in Seed Funding

NEW YORK – Swiss RNA analysis company Alithea Genomics said on Tuesday that it has closed a CHF 1 million (roughly $1 million) seed financing round, led by the Novalis Biotech Acceleration fund with participation of Switzerland-based private investors. 

Alithea, a 2020 spinout from the Swiss Federal institute of Technology (EPFL) Lausanne, has developed a proprietary technology called Bulk RNA Barcoding and sequencing (BRB-seq), which enables the preparation of hundreds of RNA samples for sequencing in a single tube.

The funding will be used to expand the commercialization and scale-up of the company's new sequencing library preparation products, Mercurius BRB-seq and Mercurius Blood BRB-seq.

“Alithea’s BRB-seq-based products have the potential to be adopted on a massive scale and expand into new and substantial industrial sectors, such as drug screening and biobank functionalization,” said Jan Van den Berghe, cofounder and managing director of Novalis Biotech, who has also been appointed to Alithea’s board of directors.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.